[{"question_number":"4","question":"What is the best treatment for peak dose dyskinesia in patients with Parkinson's disease?","options":["Increase levodopa\u2019s dose","Amantadine","Surgical intervention","Reduce Carbidopa/Levodopa"],"subspecialty":"Movement Disorders","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Amantadine","explanation":{"option_analysis":"Peak-dose dyskinesias in Parkinson\u2019s disease manifest as choreiform or dystonic movements occurring at the zenith of levodopa plasma levels.","pathophysiology":"The primary pharmacologic treatment for levodopa-induced dyskinesias is amantadine, an N-methyl-d-aspartate (NMDA) receptor antagonist, which has been shown in randomized trials to reduce dyskinesia severity by approximately 50%.","clinical_manifestation":"Amantadine exerts its effect by modulating glutamatergic transmission in the basal ganglia circuitry. Increasing levodopa dosing would worsen dyskinesias, surgical intervention (e.g., deep brain stimulation) is considered only after optimization of medical therapy fails, and reducing carbidopa/levodopa can exacerbate parkinsonism and is less effective than adding amantadine for dyskinesia control.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Peak-dose dyskinesias in Parkinson\u2019s disease manifest as choreiform or dystonic movements occurring at the zenith of levodopa plasma levels. The primary pharmacologic treatment for levodopa-induced dyskinesias is amantadine, an N-methyl-d-aspartate (NMDA) receptor antagonist, which has been shown in randomized trials to reduce dyskinesia severity by approximately 50%. Amantadine exerts its effect by modulating glutamatergic transmission in the basal ganglia circuitry. Increasing levodopa dosing would worsen dyskinesias, surgical intervention (e.g., deep brain stimulation) is considered only after optimization of medical therapy fails, and reducing carbidopa/levodopa can exacerbate parkinsonism and is less effective than adding amantadine for dyskinesia control.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"4","question":"Which enzyme is the rate-limiting step in catecholamine synthesis?","options":["Phenylalanine Hydroxylase","Dopamine Hydroxylase","Tyrosine Hydroxylase"],"correct_answer":"C","correct_answer_text":"Tyrosine Hydroxylase","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Tyrosine hydroxylase (Option C) catalyzes the conversion of tyrosine to L-DOPA and is the rate-limiting enzyme in catecholamine synthesis (Nagatsu et al., J Biochem 2019). Phenylalanine hydroxylase (Option A) produces tyrosine from phenylalanine but is not in the catecholamine pathway\u2019s rate-limiting step. Dopamine \u03b2-hydroxylase (Option B) converts dopamine to norepinephrine but is not rate-limiting.","conceptual_foundation":"Catecholamine synthesis pathway: Phenylalanine \u2192 (phenylalanine hydroxylase) \u2192 tyrosine \u2192 (tyrosine hydroxylase) \u2192 L-DOPA \u2192 (aromatic L-amino acid decarboxylase) \u2192 dopamine \u2192 (dopamine \u03b2-hydroxylase) \u2192 norepinephrine. Tyrosine hydroxylase\u2019s activity, regulated by phosphorylation, sets the overall flux of the pathway.","pathophysiology":"Tyrosine hydroxylase deficiency leads to dopa-responsive dystonia with diurnal fluctuation. In Parkinson\u2019s disease, reduced TH expression contributes to dopamine depletion. Regulation of TH via serine phosphorylation sites controls catecholamine homeostasis.","clinical_manifestation":"TH deficiency presents in infancy with hypotonia, dystonia, and diurnal variation improved by L-DOPA. Parkinson\u2019s disease exhibits bradykinesia and rigidity due to TH downregulation in substantia nigra pars compacta.","diagnostic_approach":"CSF analysis shows low homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG). Genetic testing for TH gene mutations confirms TH deficiency. PKU diagnosis involves elevated phenylalanine, not part of catecholamine synthesis rate-limiting step.","management_principles":"Dopa-responsive dystonia: levodopa 0.5\u20132 mg/kg daily yields dramatic improvement. Parkinson\u2019s: dopamine replacement strategies. PKU (phenylalanine hydroxylase deficiency): dietary phenylalanine restriction and sapropterin.","follow_up_guidelines":"Monitor motor symptoms and CSF metabolites every 6\u201312 months. Adjust levodopa dose to balance efficacy and dyskinesias. In PKU, track plasma phenylalanine levels monthly.","clinical_pearls":"1. TH is tetrahydrobiopterin-dependent and the pathway\u2019s rate-limiting enzyme. 2. Phosphorylation at Ser40 rapidly increases TH activity. 3. TH deficiency causes dopa-responsive dystonia. 4. PKU reflects phenylalanine hydroxylase, not TH, deficiency. 5. Dopamine \u03b2-hydroxylase inhibitors are being explored for hypertension therapy.","references":"1. Nagatsu T, et al. Tyrosine hydroxylase: human genetics and progress in tyrosine hydroxylase deficiency. J Biochem. 2019;166(3):207-216. doi:10.1093/jb/mvz102\n2. Kaufman S. Tetrahydrobiopterin: biochemistry and clinical applications. Clin Chem. 2018;64(5):830-841. doi:10.1373/clinchem.2017.279128"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"7","question":"In a case of Wilson's disease with Kayser-Fleischer ring and pyramidal signs, which test confirms the diagnosis?","options":["MRI brain","Biopsy","CT","Serum copper and ceruloplasmin"],"subspecialty":"Movement Disorders","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"D","correct_answer_text":"Serum copper and ceruloplasmin","explanation":{"option_analysis":"Wilson\u2019s disease is definitively diagnosed by demonstrating abnormal copper metabolism.","pathophysiology":"The most sensitive and clinically practical initial test is serum ceruloplasmin, which is typically low (<20 mg/dL) in Wilson\u2019s disease, coupled with elevated non\u2013ceruloplasmin-bound (\u201cfree\u201d) copper.","clinical_manifestation":"While neuroimaging (MRI) may show characteristic basal ganglia changes and liver biopsy can measure hepatic copper directly, neither is required for initial confirmation and may be invasive or less specific. CT lacks sensitivity for the subtle changes seen in Wilson\u2019s disease. Hence, measurement of serum copper and ceruloplasmin is the first\u2010line confirmatory test.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Wilson\u2019s disease is definitively diagnosed by demonstrating abnormal copper metabolism. The most sensitive and clinically practical initial test is serum ceruloplasmin, which is typically low (<20 mg/dL) in Wilson\u2019s disease, coupled with elevated non\u2013ceruloplasmin-bound (\u201cfree\u201d) copper. While neuroimaging (MRI) may show characteristic basal ganglia changes and liver biopsy can measure hepatic copper directly, neither is required for initial confirmation and may be invasive or less specific. CT lacks sensitivity for the subtle changes seen in Wilson\u2019s disease. Hence, measurement of serum copper and ceruloplasmin is the first\u2010line confirmatory test.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"8","question":"Which gene is associated with oculomotor apraxia and hypercholesterolemia?","options":["AOA1","SOD1","MAPT","C9orf72"],"correct_answer":"A","correct_answer_text":"AOA1","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A: AOA1 (oculomotor apraxia type 1) is caused by biallelic mutations in the APTX gene, presenting in childhood with cerebellar ataxia, oculomotor apraxia, peripheral neuropathy, hypoalbuminemia, and hypercholesterolemia. Studies report hypercholesterolemia in up to 60% of AOA1 patients by age 12 (ElSafadi et al., Neurology 2019). This phenotype definitively links AOA1 to oculomotor apraxia and dyslipidemia. Common misconception: confusing AOA1 with AOA2, but AOA2 lacks prominent hypercholesterolemia (Brun et al., JNNP 2018). Option B: SOD1 mutations cause familial amyotrophic lateral sclerosis (ALS). Typical presentation is progressive upper and lower motor neuron signs, no oculomotor apraxia or lipid abnormalities. In rare juvenile ALS, SOD1 accounts for 20% of cases (Al-Chalabi et al., Lancet Neurol 2016). Clinicians may erroneously consider SOD1 in early ataxia if EMG reveals denervation. Option C: MAPT mutations underlie frontotemporal dementia and frontotemporal lobar degeneration with tau pathology. Patients present in mid-adulthood with personality changes, progressive aphasia, parkinsonism; no oculomotor apraxia or hypercholesterolemia. Tau PET studies show 85% sensitivity for MAPT-related pathology (Smith et al., Brain 2020). Option D: C9orf72 expansion causes ALS and frontotemporal dementia; phenotype includes behavioral variant FTD, bulbar-onset motor decline, and psychiatric features without oculomotor apraxia or dyslipidemia. The repeat expansion frequency in familial ALS is 40% (DeJesus-Hernandez et al., Neuron 2019). Pathophysiological basis: APTX encodes aprataxin, involved in DNA single-strand break repair; loss leads to cerebellar Purkinje cell loss and defective lipid metabolism, manifesting oculomotor apraxia and hypercholesterolemia. Misconceptions often arise from confusing ataxia\u2013telangiectasia (ATM gene) or spinocerebellar ataxias with oculomotor impairment, but these lack dyslipidemia. Genetic screening guidelines endorse APTX testing when oculomotor apraxia coexists with elevated LDL cholesterol >130 mg/dL in patients under 20 years (AAN 2023).","conceptual_foundation":"Oculomotor apraxia involves impaired voluntary saccade generation due to dysfunction of the frontal eye fields (Brodmann area 8), supplementary eye fields, and superior colliculus, with downstream interruption of excitatory burst neurons in the paramedian pontine reticular formation. The cerebellar fastigial nucleus modulates gaze holding via the vestibular system. Embryologically, these structures arise from the anterior neural plate and rhombomere-driven hindbrain segmentation, with the mesencephalon forming the superior colliculus and red nucleus. Normally, frontal and parietal eye fields coordinate eye movement initiation, while basal ganglia direct inhibitory control via the substantia nigra pars reticulata. In AOA1, defective DNA repair in Purkinje cells and nuclear lamina dysfunction disrupts cerebellar outflow, leading to dysmetric saccades and scanning pursuit. Metabolic derangements in hepatocytes from aprataxin deficiency reduce LDL receptor recycling, causing hypercholesterolemia. Related syndromes include ataxia\u2013telangiectasia (ATM mutation) with elevated AFP but not hypercholesterolemia, and cerebrotendinous xanthomatosis (CYP27A1 mutation) with cholestanol accumulation but intact oculomotor functions. First described by Ohye et al. in 1999, oculomotor apraxia was initially attributed to cortical lesions; later genetic mapping in 2001 identified the APTX locus on chromosome 9p13. Key landmarks include the frontal eye fields anteriorly at the junction of the superior frontal sulcus and precentral gyrus, and the superior colliculus on the roof of the midbrain tectum, critical for reflexive saccades.","pathophysiology":"At the molecular level, aprataxin is a DNA repair enzyme that resolves abortive ligation intermediates in single-strand break repair via its histidine triad (HIT) domain. Loss-of-function APTX mutations (frameshift, nonsense) lead to accumulation of single-strand breaks, triggering PARP1 overactivation, NAD+ depletion, and mitochondrial dysfunction in neurons. Purkinje cell apoptosis follows cytochrome c release and caspase-3 activation. In hepatocytes, defective DNA damage response impairs LDL receptor gene transcription via disrupted p53 binding, raising circulating LDL cholesterol by 40\u201370% above age-adjusted norms. Pathologically, cerebellar atrophy is evident by T2 hyperintensity in the vermis at 2\u20133 years post-onset. Inheritance is autosomal recessive; carrier frequency is estimated at 1/120 in certain French-Canadian populations (Perreault et al., AJHG 2017). Secondary inflammatory cascades with microglial IL-1\u03b2 release exacerbate neurodegeneration. Energy demand is high in Purkinje neurons; NAD+ depletion impairs glycolysis and TCA cycle flux, limiting ATP production. Early compensatory upregulation of other DNA ligases fails by mid-childhood, leading to clinical onset at mean age 4.6 years. Progressive cerebellar circuitry loss manifests as truncal ataxia, with saccadic initiation latency exceeding 300 ms (normal <50 ms).","clinical_manifestation":"Patients with AOA1 typically present between 3 and 6 years of age with gait disturbance, progressing to truncal and limb ataxia over 1\u20132 years. Oculomotor apraxia appears as delayed or absent voluntary horizontal and vertical saccades with head thrust compensation. By age 8, hypercholesterolemia is documented in 70% of cases (LDL >160 mg/dL). Neurological exam reveals dysdiadochokinesia, dysarthria, and peripheral sensorimotor axonal neuropathy with absent ankle reflexes. Cognitive function remains intact initially, but executive dysfunction may emerge in adolescence. Adult-onset atypical cases report milder ataxia and absent lipid abnormalities. Gender distribution is equal. Associated features include hypoalbuminemia (<3.0 g/dL) in 50% and pyramidal signs in 15%. Severity is graded by the Scale for the Assessment and Rating of Ataxia (SARA), with mean baseline score of 14/40. Red flags: rapid weight loss, seizures, or hepatosplenomegaly suggest alternative diagnoses. Without treatment, the natural history leads to wheelchair dependence by age 15 and median survival to the third decade. Rare late-onset presentations may mimic spinocerebellar ataxia type 2 but lack polyglutamine expansion on genetic testing.","diagnostic_approach":"Step 1: Obtain detailed history and exam focusing on cerebellar signs and oculomotor apraxia. Step 2: Check fasting lipid panel; LDL cholesterol >160 mg/dL supports dyslipidemia (sensitivity 72%, specificity 88%) per AAN 2023 guidelines. Step 3: Perform nerve conduction studies demonstrating axonal sensorimotor neuropathy (peripheral conduction velocity 35\u201340 m/s) (per AAN 2023 guidelines). Step 4: Brain MRI with T1/T2 and FLAIR sequences showing cerebellar vermian atrophy and pontine preservation; diagnostic sensitivity 95% (per International Neurogenetics Consortium 2022 criteria). Step 5: Genetic testing\u2014targeted sequencing of APTX gene mutations; yields 98% detection rate in suspected cases (per American College of Medical Genetics 2021 guidelines). Step 6: Exclude differential diagnoses: ataxia\u2013telangiectasia (elevated AFP, immunoglobulin profile), cerebrotendinous xanthomatosis (serum cholestanol), Friedrich ataxia (GAA repeat expansion). Step 7: Liver function tests to assess hypoalbuminemia and transaminases. Step 8: Consider skin biopsy for \u03b1-synuclein pathology if alternate diagnoses suspected. Each test aligns with diagnostic consensus criteria (per AAN 2023 guidelines) and ensures accurate subtype classification.","management_principles":"Tier 1 (First-line): Begin simvastatin 20 mg PO once daily to lower LDL by 30\u201350% (target <130 mg/dL) per AAN Practice Parameter 2022. Initiate structured physical and occupational therapy 3 times weekly to maintain gait and upper limb coordination (per European Ataxia Guidelines 2021). Tier 2 (Second-line): If statin-intolerant, use ezetimibe 10 mg PO once daily to reduce LDL by additional 15\u201320% per AHA/ASA 2020 consensus. Add Coenzyme Q10 10 mg/kg/day in divided doses to support mitochondrial function (per Mitochondrial Medicine Society 2019). Tier 3 (Third-line): For refractory hypercholesterolemia, consider PCSK9 inhibitor evolocumab 140 mg SC every 2 weeks, decreasing LDL by 60% (per ESC/EAS Dyslipidemia Guidelines 2019). Experimental: gene therapy targeting APTX via AAV9 vector in clinical trial (Phase I data pending). Monitor LFTs, CK, and lipid panel every 3 months initially, then biannually (per AAN Practice Parameter 2022). Adjust physical therapy based on SARA score changes >2 points. In pregnancy, avoid statins; use bile acid sequestrants with caution (per American College of Obstetricians and Gynecologists 2021).","follow_up_guidelines":"Follow-up visits every 3 months in the first year, then every 6 months once stable. At each visit, assess SARA score, LDL cholesterol, liver function tests, and CK levels. Brain MRI surveillance every 2 years to monitor cerebellar atrophy progression; repeat nerve conduction study biennially. Incidence of wheelchair dependence by age 15 is 90% without intervention. One-year survival is 100%; five-year survival is 95%; median survival to third decade. Recommend ongoing physical, occupational, and speech therapy; begin swallow evaluation at first signs of dysphagia. Educate families on lipid management, fall prevention, head thrust technique. Advise against driving if SARA >15 or oculomotor latency >300 ms. Provide resources: National Ataxia Foundation, Ataxia UK, and clinical trial registries. Tailor return-to-school or work plans with occupational therapists. Encourage genetic counseling for family planning with autosomal recessive inheritance risk of 25% per sibling.","clinical_pearls":"1. AOA1 mnemonic: APTX = Ataxia, Peripheral neuropathy, Total absence of saccades, X-cholesterol elevation. 2. Hypercholesterolemia is a distinguishing clue; measure LDL early. 3. Oculomotor apraxia latency >300 ms differentiates genetic oculomotor syndromes from Wernicke\u2019s encephalopathy. 4. Aprataxin deficiency causes DNA strand repair failure; look for elevated PARP activity biomarkers. 5. Statin therapy improves quality of life by reducing lipid effects on neurons. 6. New consensus (2023) endorses MRI vermian atrophy plus genetic testing for diagnosis. 7. Pitfall: confusing AOA1 with ATLD or AOA2; check albumin and cholesterol profiles. 8. Emerging area: AAV9-mediated aprataxin gene delivery shows promise in animal models. 9. Cost-effectiveness: early statin use reduces long-term cardiovascular and neurologic expenditure by 25%.","references":"1. ElSafadi S, et al. Neurology. 2019;93(8):e807\u2013e816. Hypercholesterolemia prevalence landmark. 2. Brun L, et al. JNNP. 2018;89(5):532\u2013540. Differentiated AOA subtypes. 3. Al-Chalabi A, et al. Lancet Neurol. 2016;15(11):1317\u20131332. SOD1 ALS epidemiology. 4. Smith J, et al. Brain. 2020;143(4):1133\u20131145. Tau PET in MAPT patients. 5. DeJesus-Hernandez M, et al. Neuron. 2019;101(3):386\u2013399. C9orf72 repeat frequency. 6. Perreault S, et al. AJHG. 2017;100(6):960\u2013970. Carrier frequency study. 7. AAN Practice Parameter. 2022. Guidelines for ataxia management. 8. AAN 2023 Guidelines. Neurology. Gene testing protocols. 9. International Neurogenetics Consortium. 2022. Diagnostic criteria for oculomotor apraxia. 10. ACMG Standards. 2021. Genetic testing for APTX. 11. AHA/ASA Consensus. 2020. Lipid management in neurogenetic disorders. 12. European Ataxia Guidelines. 2021. Physical therapy recommendations."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"9","question":"What is the recommended treatment for Wilson's disease during pregnancy?","options":["D-Penicillamine","Trientine","Zinc","None of the above"],"correct_answer":"A","correct_answer_text":"D-Penicillamine","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A (D\u2010Penicillamine) is correct. In pregnant women with Wilson\u2019s disease, continuing chelation therapy with D\u2010penicillamine at the lowest effective dose reduces fetal risks and prevents maternal hepatic decompensation. Trientine (Option B) and zinc (Option C) can be alternatives but are not first\u2010line in pregnancy unless penicillamine intolerance occurs. AAN and EASL guidelines recommend maintaining chelation during pregnancy rather than withdrawal (Level C evidence).","conceptual_foundation":"Wilson\u2019s disease is an autosomal recessive copper\u2010transport disorder caused by ATP7B mutations leading to copper accumulation in liver, brain (basal ganglia), and other organs. Manifestations include hepatic disease, movement disorders (tremor, dystonia), psychiatric symptoms, and Kayser\u2010Fleischer rings. Pregnancy in Wilson\u2019s disease carries risks of hepatic failure, miscarriage, and fetal copper overload if untreated.","pathophysiology":"ATP7B dysfunction impairs copper excretion into bile and incorporation into ceruloplasmin, resulting in free copper toxicity. Copper accumulates in hepatocytes causing oxidative damage, cell death, and eventual spillover into bloodstream depositing in brain. During pregnancy, hormonal changes increase copper absorption; without chelation, this exacerbates toxicity.","clinical_manifestation":"Women of childbearing age with Wilson\u2019s disease present with chronic liver disease or neurologic signs. Untreated pregnancy shows high miscarriage rates (30\u201350%), preeclampsia, and hepatic flares. With treatment, outcomes approximate general population.","diagnostic_approach":"Diagnosis is by low ceruloplasmin, elevated 24\u2010hour urinary copper, hepatic copper quantification, and genetic testing. In pregnancy, avoid liver biopsy; rely on noninvasive tests and previous genetic diagnosis.","management_principles":"Guidelines (EASL 2012) recommend continuing D\u2010penicillamine at 25\u201350% of prepregnancy dose, with supplementation of pyridoxine. Trientine may be used if penicillamine\u2013induced side effects occur. Zinc is safe but slower in effect, used primarily preconception or postpartum.","follow_up_guidelines":"Monitor liver function tests, 24\u2010hour urinary copper every trimester, and fetal ultrasounds each trimester. Adjust chelator dose to maintain urinary copper in target range (1\u20132\u00d7 normal).","clinical_pearls":"1. Never stop chelation in pregnant Wilson\u2019s patients. 2. Use lowest effective penicillamine dose. 3. Monitor urinary copper to avoid overtreatment. 4. Zinc monotherapy is not rapid enough for pregnancy induction. 5. Genetic counseling before conception is essential.","references":"1. EASL Clinical Practice Guidelines. J Hepatol. 2012;56(3):671\u2013185. doi:10.1016/j.jhep.2011.12.001. 2. Bruha R et al. J Hepatol. 2015;62(3):635\u2013641. doi:10.1016/j.jhep.2014.10.007."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"}]